Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone and Avonex in RRMS (NORM)
NCT00168766Phase 4Completed
- Sponsor
- Biogen
- Start
- Jan 2003
- Primary completion
- Nov 2008
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 4, randomised, double-blind trial in multiple sclerosis (MS) comparing Methylprednisolone + Avonex with Placebo + Avonex (2 arms). Primary endpoint: Time to onset of disability progression sustained over at least 6 months. Started Jan 2003; status: completed.
02
Drugs
methylprednisolone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00168766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168766.